Compare Amgen, Inc. (AMGN) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Boeing Co — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Boeing Co trades at $222.03 (market cap $175.22B). The key difference: Amgen, Inc. and Boeing Co are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BA | |
|---|---|---|
Market Cap | $196.12B | $175.22B |
Sector | Health | Industrials |
52-Week High | $388.16 | $252.15 |
52-Week Low | $271.18 | $179.12 |
Enterprise Value | $241.41B | $201.53B |
Dividend Yield | 2.77% | 0.03% |
Volume | — | 7,591,579 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Boeing (BA) trades at $222.28, down 0.37% on the day, with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with 2025 revenue of $89.46B and net income of $2.24B, reversing previous losses. Recent news includes both positive developments like new aircraft orders and regulatory milestones, alongside ongoing safety concerns highlighted by recent incidents.
The outlook is cautiously optimistic with a $268.33 consensus price target representing 21% upside. Key opportunities include production expansion and defense contracts, while risks center on operational execution, debt burden, and persistent safety-related headline volatility that could impact investor confidence and regulatory timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
